- in the opinion of the investigator, unlikely to survive after 48 hours, or unlikely to remain at the investigational site beyond 48 hours - participants requiring use of invasive or non-invasive positive pressure ventilation at randomization. - presence of significant liver enzyme abnormalities, thrombocytopenia or anemia at screening. - any prior or concurrent use or plans to receive during the study period of immunomodulatory therapies (other than interventional drug) at screening. - use of chronic systemic corticosteroids for a non-covid-19-related condition in a dose higher than prednisone 10 mg or equivalent per day at screening. - exclusion criteria related to tuberculosis (tb) and non-tuberculous mycobacterial (ntm) infections. - participants with suspected or known active systemic bacterial or fungal infections within 4 weeks of screening. - pregnant or breastfeeding women. - in the opinion of the study investigator, might confound the results of the study or pose an undue risk to the safety of the participant. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- in the opinion of the investigator, unlikely to survive after 48 hours, or unlikely to remain at the investigational site beyond 48 hours - participants requiring use of invasive or non-invasive positive pressure ventilation at randomization. - presence of significant liver enzyme abnormalities, thrombocytopenia or anemia at screening. - any prior or concurrent use or plans to receive during the study period of immunomodulatory therapies (other than interventional drug) at screening. - use of chronic systemic corticosteroids for a non-covid-19-related condition in a dose higher than prednisone 10 mg or equivalent per day at screening. - exclusion criteria related to tuberculosis (tb) and non-tuberculous mycobacterial (ntm) infections. - participants with suspected or known active systemic bacterial or fungal infections within 4 weeks of screening. - pregnant or breastfeeding women. - in the opinion of the study investigator, might confound the results of the study or pose an undue risk to the safety of the participant. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.